Dear Dr. Tammara:

Please refer to your supplemental new drug application dated August 31, 2005, received September 1, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vytorin (ezetimibe/simvastatin) Tablets.

We acknowledge receipt of your submission dated December 2 (email), 2005.

This supplemental new drug application provides for additional bottle package configuration for the 10/40 and 10/80 bottle count. Additionally, this application provides for changes to the HOW SUPPLIED section of the Vytorin package insert.

To the HOW SUPPLIED section, No. 3875 – Tablets Vytorin 10/40 subsection, the following information has been added:

NDC 66582-313-86 bottles of 5000 (If repackaged in blisters, then opaque or light-resistant blisters should be used.)

To the HOW SUPPLIED section, No. 3876 – Tablets Vytorin 10/80 subsection, the following information has been added:

NDC 66582-315-66 bottles of 2500 (If repackaged in blisters, then opaque or light-resistant blisters should be used.)

Additionally, the Vytorin 10/40 5000-count bottle and the Vytorin 10/80 2500-count bottle were added to the title and instructions for 10,000-count bottle storage statement.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed draft labeling [package insert submitted December 2 (email), 2005].
Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-687/S-009**." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
Food and Drug Administration  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

**MEDWATCH**  
Food and Drug Administration  
WO 22, Room 4447  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, M.S., R.Ph., Regulatory Project Manager, at (301) 796-1295.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.  
Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Mary Parks
12/9/2005 02:31:25 PM
for Dr. Orloff